Korea's PharmGen Science to lead commercialization of world's first Covid-19 biosimilar

Lee Byung-moon and Minu Kim 2021. 9. 23. 14:36
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

PharmGen Science, a Korean biotech company, Thursday announced it has signed a memorandum of understanding (MOU) with U.S.-based AccessBio and IVY Pharma to co-develop and commercialize a biosimilar of an mRNA vaccine against Covid-19.

The MOU was signed during the KORUS Global Vaccine Business Round Table held in New York on Tuesday.

PharmGen Science is the largest shareholder of AccessBio. IVY Pharma, founded in 2005 in New Jersey, has been dedicated to the development of biopharmaceuticals and biosimilars. IVY Pharma has launched biosimilar products in more than 30 countries through various global alliances and partnerships.

Scientists have studied and developed an mRNA vaccine for more than 10 years with a goal of eradicating cancer, but the research was redirected as a preventive vaccine for Covid-19.

Under the MOU, PharmGen Science and AccessBio will jointly cover the expenses for the vaccine development project. They will directly participate in the commercial development of IVY Pharma's Covid-19 mRNA vaccine biosimilar and regulatory approval.

PharmGen Science said the three companies have been pursuing strategic cooperation with the goal of resolving imbalances in the global vaccine supply.

The project is about the investment in the commercial development of the world's first mRNA Covid-19 vaccine biosimilar candidate which was initiated by IVY Pharma's chief technology officer Dr. Sarfaraz Niazi, said an official from PharmGen Science.

The former University of Illinois at Chicago professor is a pioneer in the field of biosimilars recognized worldwide. He has developed more than 1,000 generic, oncology, and biologic products.

Forbes Magazine recognized his lifetime’s achievement by calling him as 'the Most Interesting Man Revolutionizing the Health World'.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?